
Sign up to save your podcasts
Or
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers—but science is making real progress. In this episode, Dr. Eytan Stein of Memorial Sloan Kettering breaks down what makes AML so challenging to treat, how it’s classified, and the latest therapies changing the outlook for patients. From combination therapies and menin inhibitors to future research on CAR T-cell therapy and bispecifics, this is a hopeful, expert-led look at the future of AML treatment.
Mentioned on this episode:
Additional LLS Support Resources:
Supported by Abbvie Inc.; Astellas Pharma US Inc.; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.
The post Understanding AML: The Challenges, The Progress, The Hope first appeared on The Bloodline with LLS.
4.9
4545 ratings
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers—but science is making real progress. In this episode, Dr. Eytan Stein of Memorial Sloan Kettering breaks down what makes AML so challenging to treat, how it’s classified, and the latest therapies changing the outlook for patients. From combination therapies and menin inhibitors to future research on CAR T-cell therapy and bispecifics, this is a hopeful, expert-led look at the future of AML treatment.
Mentioned on this episode:
Additional LLS Support Resources:
Supported by Abbvie Inc.; Astellas Pharma US Inc.; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.
The post Understanding AML: The Challenges, The Progress, The Hope first appeared on The Bloodline with LLS.
10,326 Listeners
27,080 Listeners
12,901 Listeners
43,353 Listeners
14,899 Listeners
1,881 Listeners
9,285 Listeners
3,722 Listeners
4,129 Listeners
38,584 Listeners
41,407 Listeners
169 Listeners
7,127 Listeners
19,449 Listeners
708 Listeners